Search

Your search keyword '"Vermeer, Maarten H."' showing total 632 results
Start Over Author "Vermeer, Maarten H."
632 results on '"Vermeer, Maarten H."'

5. Deep Learning–Based Classification of Early-Stage Mycosis Fungoides and Benign Inflammatory Dermatoses on H&E-Stained Whole-Slide Images: A Retrospective, Proof-of-Concept Study

Author

Doeleman, Thom, Brussee, Siemen, Hondelink, Liesbeth M., Westerbeek, Daniëlle W.F., Sequeira, Ana M., Valkema, Pieter A., Jansen, Patty M., He, Junling, Vermeer, Maarten H., Quint, Koen D., van Dijk, Marijke R., Verbeek, Fons J., Kers, Jesper, and Schrader, Anne M.R.

Published
2024
Full Text
View/download PDF

7. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023

Author

Latzka, Johanna, Assaf, Chalid, Bagot, Martine, Cozzio, Antonio, Dummer, Reinhard, Guenova, Emmanuella, Gniadecki, Robert, Hodak, Emmilia, Jonak, Constanze, Klemke, Claus-Detlev, Knobler, Robert, Morrris, Stephen, Nicolay, Jan P., Ortiz-Romero, Pablo L., Papadavid, Evangelia, Pimpinelli, Nicola, Quaglino, Pietro, Ranki, Annamari, Scarisbrick, Julia, Stadler, Rudolf, Väkevä, Liisa, Vermeer, Maarten H., Wehkamp, Ulrike, Whittaker, Sean, Willemze, Rein, and Trautinger, Franz

Published
2023
Full Text
View/download PDF

16. Paediatric-onset lymphomatoid papulosis: results of a multicentre retrospective cohort study on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG).

Author

Blanchard, Maël, Morren, Marie-Anne, Busschots, Anne-Marie, Hauben, Esther, Alberti-Violetti, Silvia, Berti, Emilio, Avallone, Gianluca, Tavoletti, Gianluca, Panzone, Michele, Quaglino, Pietro, Colonna, Cristiana, Melchers, Rutger C, Vermeer, Maarten H, Gniadecki, Robert, Mitteldorf, Christina, Gosmann, Janika, Stadler, Rudolf, Jonak, Constanze, Oren-Shabtai, Meital, and Hodak, Emmilia

Subjects
ANAPLASTIC large-cell lymphoma, CHILD patients, ACUTE myeloid leukemia, COHORT analysis, MYCOSIS fungoides, SEZARY syndrome
Abstract

Background Lymphomatoid papulosis (LyP) is a rare cutaneous T-cell lymphoproliferative disorder. Comprehensive data on LyP in the paediatric population are scarce. Objectives To characterize the epidemiological, clinical, histopathological and prognostic features of paediatric LyP. Methods This was a retrospective multicentre international cohort study that included 87 children and adolescents with LyP diagnosed between 1998 and 2022. Patients aged ≤ 18 years at disease onset were included. LyP diagnosis was made in each centre, based on clinicopathological correlation. Results Eighty-seven patients from 12 centres were included. Mean age at disease onset was 7.0 years (range 3 months–18 years) with a male to female ratio of 2 : 1. Mean time between the onset of the first cutaneous lesions and diagnosis was 1.3 years (range 0–14). Initial misdiagnosis concerned 26% of patients. LyP was most often misdiagnosed as pityriasis lichenoides et varioliformis acuta, insect bites or mollusca contagiosa. Erythematous papules or papulonodules were the most frequent clinical presentation. Pruritus was specifically mentioned in 21% of patients. The main histological subtype was type A in 55% of cases. When analysed, monoclonal T-cell receptor rearrangement was found in 77% of skin biopsies. The overall survival rate was 100%, with follow-up at 5 years available for 33 patients and at 15 years for 8 patients. Associated haematological malignancy (HM) occurred in 10% of cases (n = 7/73), including four patients with mycosis fungoides, one with primary cutaneous anaplastic large cell lymphoma (ALCL), one with systemic ALCL and one with acute myeloid leukaemia. If we compared incidence rates of cancer with the world population aged 0–19 years from 2001 to 2010, we estimated a significantly higher risk of associated malignancy in general, occurring before the age of 19 years (incidence rate ratio 87.49, 95% confidence interval 86.01–88.99). Conclusions We report epidemiological data from a large international cohort of children and adolescents with LyP. Overall, the disease prognosis is good, with excellent survival rates for all patients. Owing to an increased risk of associated HM, long-term follow-up should be recommended for patients with LyP. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Cutaneous T cell lymphoma

Author

Dummer, Reinhard, Vermeer, Maarten H., Scarisbrick, Julia J., Kim, Youn H., Stonesifer, Connor, Tensen, Cornelis P., Geskin, Larisa J., Quaglino, Pietro, and Ramelyte, Egle

Published
2021
Full Text
View/download PDF

25. Elucidating genetic factors of cutaneous T-cell lymphoma staging and disease severity through machine learning

Author

Schreidah, Celine M., primary, Reynolds, George Bingham, additional, Shen, Haoyang, additional, Fahmy, Lauren M., additional, Choi, Jaehyuk, additional, Duvic, Madeleine, additional, Gallardo, Fernando, additional, Girardi, Michael, additional, Guitart, Joan, additional, Kim, Youn H., additional, Khodadoust, Michael, additional, Najidh, Safa, additional, Ni, Xiao, additional, Pujol, Ramon M., additional, Tensen, Cornelis P., additional, Vermeer, Maarten H., additional, Whittaker, Sean, additional, Tatonetti, Nicholas P., additional, Chase, Herbert S., additional, Pe’er, Itsik, additional, and Geskin, Larisa J., additional

Published
2023
Full Text
View/download PDF

28. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017

Author

Trautinger, Franz, Eder, Johanna, Assaf, Chalid, Bagot, Martine, Cozzio, Antonio, Dummer, Reinhard, Gniadecki, Robert, Klemke, Claus-Detlev, Ortiz-Romero, Pablo L., Papadavid, Evangelia, Pimpinelli, Nicola, Quaglino, Pietro, Ranki, Annamari, Scarisbrick, Julia, Stadler, Rudolf, Väkevä, Liisa, Vermeer, Maarten H., Whittaker, Sean, Willemze, Rein, and Knobler, Robert

Published
2017
Full Text
View/download PDF

29. "Next top" mouse models advancing CTCL research.

Author

Yixin Luo, de Gruij, Frank R., Vermeer, Maarten H., and Tensen, Cornelis P.

Subjects
LABORATORY mice, ANIMAL disease models, DRUG efficacy, CUTANEOUS T-cell lymphoma, T cells
Abstract

This review systematically describes the application of in vivo mouse models in studying cutaneous T-cell lymphoma (CTCL), a complex hematological neoplasm. It highlights the diverse research approaches essential for understanding CTCL's intricate pathogenesis and evaluating potential treatments. The review categorizes various mouse models, including xenograft, syngeneic transplantation, and genetically engineered mouse models (GEMMs), emphasizing their contributions to understanding tumorhost interactions, gene functions, and studies on drug efficacy in CTCL. It acknowledges the limitations of these models, particularly in fully replicating human immune responses and early stages of CTCL. The review also highlights novel developments focusing on the potential of skin-targeted GEMMs in studying natural skin lymphoma progression and interactions with the immune system from onset. In conclusion, a balanced understanding of these models' strengths and weaknesses are essential for accelerating the deciphering of CTCL pathogenesis and developing treatment methods. The GEMMs engineered to target specifically skin-homing CD4+ T cells can be the next top mouse models that pave the way for exploring the effects of CTCL-related genes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Evaluation of Quality of Life and Treatment Satisfaction in Newly Diagnosed Cutaneous T-Cell Lymphoma Patients.

Author

Ottevanger, Rosanne, van Beugen, Sylvia, Kersten, Juliette M., Evers, Andrea W. M., Vermeer, Maarten H., Willemze, Rein, and Quint, Koen D.

Subjects
PAIN measurement, ACADEMIC medical centers, RESEARCH funding, VISUAL analog scale, QUESTIONNAIRES, MYCOSIS fungoides, TREATMENT effectiveness, DESCRIPTIVE statistics, SEZARY syndrome, LONGITUDINAL method, ITCHING, CUTANEOUS T-cell lymphoma, QUALITY of life, PATIENT satisfaction, CANCER patient psychology, CANCER fatigue, PATIENTS' attitudes, DISEASE complications
Abstract

Simple Summary: This study provides an insight into newly diagnosed patients with MF on patients' expectations, quality of life, and treatment satisfaction. These data can be used for adequate expectation management and provide a rationale for further evaluation of treatment regimens in these patients. Background: Little is known about the impact of MF on quality of life (QoL) in newly diagnosed patients. Objectives: To describe the impact of the MF diagnosis on QoL, patient expectations, and treatment satisfaction over the first 6 months after diagnosis. Methods: Outcomes of this prospective cohort study of newly diagnosed MF patients conducted between 2020 and 2022 at the Leiden University Medical Center included the Skindex-29, RAND-12 Health Survey, degree of itch, pain, and fatigue (Visual Analogue Scale (VAS)), patient expectations, and Client Satisfaction Questionnaire-8 (CSQ-8), measured at baseline and after six months. Results: A total of 28 patients with MF were included. At baseline, 66% (n = 18) "strongly-totally" expected positive effects of the treatment. At the time of diagnosis, 28% of the patients (n = 8) were moderately to severely affected. There was no statistical change in the Skindex-29 score sum score (20 [10–34] vs. 20 [9–36]; p = 0.81) or in the other three subdomains, the RAND-12 scores, and the VAS itch, pain, and fatigue over time. Treatment satisfaction was high overall. Conclusion: Despite that the newly diagnosed MF patients anticipate a positive treatment effect, few improvements in QoL and symptom reduction were found. These data can be used for adequate expectation management and provide a rationale for further evaluation of treatment regimens in these patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Autoantibody subclass predominance is not driven by aberrant class switching or impaired B cell development

Author

Paardekooper, Laurent M., primary, Fillié-Grijpma, Yvonne E., additional, van der Sluijs-Gelling, Alita J., additional, Zlei, Mihaela, additional, van Doorn, Remco, additional, Vermeer, Maarten H., additional, Paunovic, Manuela, additional, Titulaer, Maarten J., additional, van der Maarel, Silvère M., additional, van Dongen, Jacques J.M., additional, Verschuuren, Jan J., additional, and Huijbers, Maartje G., additional

Published
2023
Full Text
View/download PDF

37. Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients

Author

Boonk, Stephanie E., Zoutman, Willem H., Marie-Cardine, Anne, van der Fits, Leslie, Out-Luiting, Jacoba J., Mitchell, Tracey J., Tosi, Isabella, Morris, Stephen L., Moriarty, Blaithin, Booken, Nina, Felcht, Moritz, Quaglino, Pietro, Ponti, Renata, Barberio, Emanuela, Ram-Wolff, Caroline, Jäntti, Kirsi, Ranki, Annamari, Bernengo, Maria Grazia, Klemke, Claus-Detlev, Bensussan, Armand, Michel, Laurence, Whittaker, Sean, Bagot, Martine, Tensen, Cornelis P., Willemze, Rein, and Vermeer, Maarten H.

Published
2016
Full Text
View/download PDF

38. Autoantibody subclass predominance is not driven by aberrant class switching or impaired B cell development

Author

Samenwerkende GezondheidsFondsen, Paardekooper, Laurent M., Fillié-Grijpma, Yvonne E., Sluijs-Gelling, Alita J. van der, Zlei, Mihaela, Doorn, Remco van, Vermeer, Maarten H., Paunovic, Manuela, Titulaer, Maarten J., Maarel, Silvère M. van der, Dongen, J. J. M. van, Verschuuren, Jan J., Huijbers, Maartje G., Samenwerkende GezondheidsFondsen, Paardekooper, Laurent M., Fillié-Grijpma, Yvonne E., Sluijs-Gelling, Alita J. van der, Zlei, Mihaela, Doorn, Remco van, Vermeer, Maarten H., Paunovic, Manuela, Titulaer, Maarten J., Maarel, Silvère M. van der, Dongen, J. J. M. van, Verschuuren, Jan J., and Huijbers, Maartje G.

Abstract

A subset of autoimmune diseases is characterized by predominant pathogenic IgG4 autoantibodies (IgG4-AID). Why IgG4 predominates in these disorders is unknown. We hypothesized that dysregulated B cell maturation or aberrant class switching causes overrepresentation of IgG4+ B cells and plasma cells. Therefore, we compared the B cell compartment of patients from four different IgG4-AID with two IgG1-3-AID and healthy donors, using flow cytometry. Relative subset abundance at all maturation stages was normal, except for a, possibly treatment-related, reduction in immature and naïve CD5+ cells. IgG4+ B cell and plasma cell numbers were normal in IgG4-AID patients, however they had a (sub)class-independent 8-fold increase in circulating CD20-CD138+ cells. No autoreactivity was found in this subset. These results argue against aberrant B cell development and rather suggest the autoantibody subclass predominance to be antigen-driven. The similarities between IgG4-AID suggest that, despite displaying variable clinical phenotypes, they share a similar underlying immune profile.

Published
2023

39. Data from Novel and Highly Recurrent Chromosomal Alterations in Sézary Syndrome

Author

Vermeer, Maarten H., primary, van Doorn, Remco, primary, Dijkman, Remco, primary, Mao, Xin, primary, Whittaker, Sean, primary, van Voorst Vader, Pieter C., primary, Gerritsen, Marie-Jeanne P., primary, Geerts, Marie-Louise, primary, Gellrich, Sylke, primary, Söderberg, Ola, primary, Leuchowius, Karl-Johan, primary, Landegren, Ulf, primary, Out-Luiting, Jacoba J., primary, Knijnenburg, Jeroen, primary, IJszenga, Marije, primary, Szuhai, Karoly, primary, Willemze, Rein, primary, and Tensen, Cornelis P., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 1 from Novel and Highly Recurrent Chromosomal Alterations in Sézary Syndrome

Author

Vermeer, Maarten H., primary, van Doorn, Remco, primary, Dijkman, Remco, primary, Mao, Xin, primary, Whittaker, Sean, primary, van Voorst Vader, Pieter C., primary, Gerritsen, Marie-Jeanne P., primary, Geerts, Marie-Louise, primary, Gellrich, Sylke, primary, Söderberg, Ola, primary, Leuchowius, Karl-Johan, primary, Landegren, Ulf, primary, Out-Luiting, Jacoba J., primary, Knijnenburg, Jeroen, primary, IJszenga, Marije, primary, Szuhai, Karoly, primary, Willemze, Rein, primary, and Tensen, Cornelis P., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table 4 from Novel and Highly Recurrent Chromosomal Alterations in Sézary Syndrome

Author

Vermeer, Maarten H., primary, van Doorn, Remco, primary, Dijkman, Remco, primary, Mao, Xin, primary, Whittaker, Sean, primary, van Voorst Vader, Pieter C., primary, Gerritsen, Marie-Jeanne P., primary, Geerts, Marie-Louise, primary, Gellrich, Sylke, primary, Söderberg, Ola, primary, Leuchowius, Karl-Johan, primary, Landegren, Ulf, primary, Out-Luiting, Jacoba J., primary, Knijnenburg, Jeroen, primary, IJszenga, Marije, primary, Szuhai, Karoly, primary, Willemze, Rein, primary, and Tensen, Cornelis P., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table 3 from Novel and Highly Recurrent Chromosomal Alterations in Sézary Syndrome

Author

Vermeer, Maarten H., primary, van Doorn, Remco, primary, Dijkman, Remco, primary, Mao, Xin, primary, Whittaker, Sean, primary, van Voorst Vader, Pieter C., primary, Gerritsen, Marie-Jeanne P., primary, Geerts, Marie-Louise, primary, Gellrich, Sylke, primary, Söderberg, Ola, primary, Leuchowius, Karl-Johan, primary, Landegren, Ulf, primary, Out-Luiting, Jacoba J., primary, Knijnenburg, Jeroen, primary, IJszenga, Marije, primary, Szuhai, Karoly, primary, Willemze, Rein, primary, and Tensen, Cornelis P., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Table 2 from Novel and Highly Recurrent Chromosomal Alterations in Sézary Syndrome

Author

Vermeer, Maarten H., primary, van Doorn, Remco, primary, Dijkman, Remco, primary, Mao, Xin, primary, Whittaker, Sean, primary, van Voorst Vader, Pieter C., primary, Gerritsen, Marie-Jeanne P., primary, Geerts, Marie-Louise, primary, Gellrich, Sylke, primary, Söderberg, Ola, primary, Leuchowius, Karl-Johan, primary, Landegren, Ulf, primary, Out-Luiting, Jacoba J., primary, Knijnenburg, Jeroen, primary, IJszenga, Marije, primary, Szuhai, Karoly, primary, Willemze, Rein, primary, and Tensen, Cornelis P., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Table 1 from Novel and Highly Recurrent Chromosomal Alterations in Sézary Syndrome

Author

Vermeer, Maarten H., primary, van Doorn, Remco, primary, Dijkman, Remco, primary, Mao, Xin, primary, Whittaker, Sean, primary, van Voorst Vader, Pieter C., primary, Gerritsen, Marie-Jeanne P., primary, Geerts, Marie-Louise, primary, Gellrich, Sylke, primary, Söderberg, Ola, primary, Leuchowius, Karl-Johan, primary, Landegren, Ulf, primary, Out-Luiting, Jacoba J., primary, Knijnenburg, Jeroen, primary, IJszenga, Marije, primary, Szuhai, Karoly, primary, Willemze, Rein, primary, and Tensen, Cornelis P., primary

Published
2023
Full Text
View/download PDF

46. Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510

Author

Wind, Selinde S., primary, Jansen, Manon A. A., additional, Rijsbergen, Melanie, additional, van Esdonk, Michiel J., additional, Ziagkos, Dimitrios, additional, Cheng, Wing C., additional, Niemeyer-van der Kolk, Tessa, additional, Korsten, John, additional, Gruszka, Agnieszka, additional, Schmitz-Rohmer, Debora, additional, Bonnel, David, additional, Legouffe, Raphael, additional, Barré, Florian, additional, Bekkenk, Marcel W., additional, de Haas, Ellen R. M., additional, Quint, Koen D., additional, Schnidar, Harald, additional, Rolli, Melanie, additional, Streefkerk, Henk Johan, additional, Burggraaf, Jacobus, additional, Vermeer, Maarten H., additional, and Rissmann, Robert, additional

Published
2023
Full Text
View/download PDF

47. O-134 - Elucidating genetic factors of cutaneous T-cell lymphoma staging and disease severity through machine learning

Author

Schreidah, Celine M., Reynolds, George Bingham, Shen, Haoyang, Fahmy, Lauren M., Choi, Jaehyuk, Duvic, Madeleine, Gallardo, Fernando, Girardi, Michael, Guitart, Joan, Kim, Youn H., Khodadoust, Michael, Najidh, Safa, Ni, Xiao, Pujol, Ramon M., Tensen, Cornelis P., Vermeer, Maarten H., Whittaker, Sean, Tatonetti, Nicholas P., Chase, Herbert S., Pe’er, Itsik, and Geskin, Larisa J.

Published
2023
Full Text
View/download PDF

48. Correction:Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510)

Author

Wind, Selinde S., Jansen, Manon A. A., Rijsbergen, Melanie, van Esdonk, Michiel J., Ziagkos, Dimitrios, Cheng, Wing C., Niemeyer-van der Kolk, Tessa, Korsten, John, Gruszka, Agnieszka, Schmitz-Rohmer, Debora, Bonnel, David, Legouffe, Raphael, Barré, Florian, Bekkenk, Marcel W., de Haas, Ellen R. M., Quint, Koen D., Schnidar, Harald, Rolli, Melanie, Streefkerk, Henk Johan, Burggraaf, Jacobus, Vermeer, Maarten H., and Rissmann, Robert

Abstract

The authors wish to make the following corrections to this paper [1]: 1. ‘Harald Schnidar’ was not included as an author in the published article and he was added as the co-author including his affiliation 8. The corrected Author Contributions Statement was updated as follows:.

Published
2023
Full Text
View/download PDF

49. Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510)

Author

Wind, Selinde S., Jansen, Manon A. A., Rijsbergen, Melanie, van Esdonk, Michiel J., Ziagkos, Dimitrios, Cheng, Wing C., Niemeyer-van der Kolk, Tessa, Korsten, John, Gruszka, Agnieszka, Schmitz-Rohmer, Debora, Bonnel, David, Legouffe, Raphael, Barré, Florian, Bekkenk, Marcel W., de Haas, Ellen R. M., Quint, Koen D., Schnidar, Harald, Rolli, Melanie, Streefkerk, Henk Johan, Burggraaf, Jacobus, Vermeer, Maarten H., Rissmann, Robert, Dermatology, Obstetrics and Gynaecology, Amsterdam Reproduction & Development (AR&D), AII - Cancer immunology, CCA - Cancer Treatment and Quality of Life, and CCA - Cancer biology and immunology

Abstract

The authors wish to make the following corrections to this paper [1]: 1. ‘Harald Schnidar’ was not included as an author in the published article and he was added as the co-author including his affiliation 8. The corrected Author Contributions Statement was updated as follows:.

Published
2023

50. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs

Author

Bagot, Martine, Hasan, Baktiar, Whittaker, Sean, Beylot-Barry, Marie, Knobler, Robert, Shah, Emad, Marreaud, Sandrine, Morris, Stephen, Dalle, Stephane, Servitje, Octavio, Cowan, Richard, Väkevä, Liisa, Chaby, Guillaume, Jonak, Constanze, Fox, Christopher P, Ritchie, Diana, Vermeer, Maarten H, Stadler, Rudolf, Romero, Pablo L Ortiz, Scarisbrick, Julia, Quaglino, Pietro, and EORTC Cutaneous T-Cell Lymphoma Task Force

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results